PortfoliosLab logoPortfoliosLab logo
AZN vs. SCHW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AZN vs. SCHW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AstraZeneca PLC (AZN) and The Charles Schwab Corporation (SCHW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AZN achieves a -1.57% return, which is significantly higher than SCHW's -8.33% return. Over the past 10 years, AZN has outperformed SCHW with an annualized return of 15.74%, while SCHW has yielded a comparatively lower 13.79% annualized return.


AZN

1D
-0.83%
1M
-2.37%
YTD
-1.57%
6M
-1.17%
1Y
22.44%
3Y*
8.11%
5Y*
11.23%
10Y*
15.74%

SCHW

1D
-0.16%
1M
0.08%
YTD
-8.33%
6M
-3.88%
1Y
5.43%
3Y*
20.37%
5Y*
5.67%
10Y*
13.79%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AZN vs. SCHW - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AZN
AstraZeneca PLC
-1.57%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%
SCHW
The Charles Schwab Corporation
-8.33%36.65%9.17%-15.97%0.11%60.23%13.57%16.38%-18.43%31.15%

Correlation

The correlation between AZN and SCHW is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.03

Correlation (3Y)
Calculated over the trailing 3-year period

0.12

Correlation (5Y)
Calculated over the trailing 5-year period

0.15

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since May 17, 1993

0.22

The correlation between AZN and SCHW shifts across timeframes, from 0.03 (1 year) to 0.22 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

AZN:

$276.72B

SCHW:

$159.34B

EPS

AZN:

$6.66

SCHW:

$5.26

PE Ratio

AZN:

26.63

SCHW:

17.28

PEG Ratio

AZN:

0.04

SCHW:

0.99

PS Ratio

AZN:

4.58

SCHW:

6.74

PB Ratio

AZN:

5.85

SCHW:

59.02K

Total Revenue (TTM)

AZN:

$60.44B

SCHW:

$24.17B

Gross Profit (TTM)

AZN:

$49.37B

SCHW:

$18.86B

EBITDA (TTM)

AZN:

$20.47B

SCHW:

$13.11B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AZN vs. SCHW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AZN
AZN Risk / Return Rank: 6868
Overall Rank
AZN Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 6767
Sortino Ratio Rank
AZN Omega Ratio Rank: 6464
Omega Ratio Rank
AZN Calmar Ratio Rank: 7070
Calmar Ratio Rank
AZN Martin Ratio Rank: 7171
Martin Ratio Rank

SCHW
SCHW Risk / Return Rank: 4747
Overall Rank
SCHW Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
SCHW Sortino Ratio Rank: 4242
Sortino Ratio Rank
SCHW Omega Ratio Rank: 4343
Omega Ratio Rank
SCHW Calmar Ratio Rank: 4949
Calmar Ratio Rank
SCHW Martin Ratio Rank: 5050
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AZN vs. SCHW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AstraZeneca PLC (AZN) and The Charles Schwab Corporation (SCHW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AZNSCHWDifference
Sharpe ratioReturn per unit of total volatility

+0.65

Sortino ratioReturn per unit of downside risk

+1.07

Omega ratioGain probability vs. loss probability

1.17

1.06

+0.11

Calmar ratioReturn relative to maximum drawdown

1.47

0.27

+1.19

Martin ratioReturn relative to average drawdown

3.82

0.64

+3.19

AZN vs. SCHW - Sharpe Ratio Comparison

The current AZN Sharpe Ratio is 0.88, which is higher than the SCHW Sharpe Ratio of 0.23. The chart below compares the historical Sharpe Ratios of AZN and SCHW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AZN vs. SCHW - Drawdown Comparison

The maximum AZN drawdown since its inception was -48.94%, smaller than the maximum SCHW drawdown of -86.79%. Use the drawdown chart below to compare losses from any high point for AZN and SCHW.


Loading charts...

Drawdown Indicators


AZNSCHWDifference

Max Drawdown

Largest peak-to-trough decline

-48.94%

-86.79%

+37.85%

Max Drawdown (1Y)

Largest decline over 1 year

-15.43%

-19.83%

+4.40%

Max Drawdown (3Y)

Largest decline over 3 years

-27.87%

-27.11%

-0.76%

Max Drawdown (5Y)

Largest decline over 5 years

-27.87%

-49.70%

+21.83%

Max Drawdown (10Y)

Largest decline over 10 years

-27.87%

-51.08%

+23.21%

Current Drawdown

Current decline from peak

-14.96%

-14.57%

-0.39%

Average Drawdown

Average peak-to-trough decline

-11.37%

-35.53%

+24.16%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.06%

8.55%

-2.49%

Volatility

AZN vs. SCHW - Volatility Comparison

AstraZeneca PLC (AZN) has a higher volatility of 7.87% compared to The Charles Schwab Corporation (SCHW) at 7.42%. This indicates that AZN's price experiences larger fluctuations and is considered to be riskier than SCHW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AZNSCHWDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.87%

7.42%

+0.45%

Volatility (6M)

Calculated over the trailing 6-month period

17.66%

19.74%

-2.08%

Volatility (1Y)

Calculated over the trailing 1-year period

25.76%

24.19%

+1.57%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

24.04%

32.21%

-8.17%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

24.93%

33.42%

-8.49%

Dividends

AZN vs. SCHW - Dividend Comparison

AZN's dividend yield for the trailing twelve months is around 3.00%, more than SCHW's 1.30% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.00%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
SCHW
The Charles Schwab Corporation
1.30%1.08%1.35%1.45%1.01%0.86%1.36%1.43%1.11%0.62%0.68%0.73%

Financials

AZN vs. SCHW - Financials Comparison

This section allows you to compare key financial metrics between AstraZeneca PLC and The Charles Schwab Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


4.00B6.00B8.00B10.00B12.00B14.00B16.00B20222023202420252026
15.29B
3.14B
(AZN) Total Revenue
(SCHW) Total Revenue
Values in USD except per share items

AZN vs. SCHW - Profitability Comparison

The chart below illustrates the profitability comparison between AstraZeneca PLC and The Charles Schwab Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
82.5%
32.7%
Portfolio components
AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

SCHW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Charles Schwab Corporation reported a gross profit of 1.03B and revenue of 3.14B. Therefore, the gross margin over that period was 32.7%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

SCHW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Charles Schwab Corporation reported an operating income of -730.00M and revenue of 3.14B, resulting in an operating margin of -23.2%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.

SCHW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Charles Schwab Corporation reported a net income of 2.48B and revenue of 3.14B, resulting in a net margin of 78.9%.


Frequently Asked Questions


AZN and SCHW have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AZN has higher volatility (7.87%) compared to SCHW (7.42%). In terms of maximum drawdown, AZN dropped -48.94% vs SCHW's -86.79%.

AZN currently has the higher Sharpe Ratio (0.88 vs 0.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AZN and SCHW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer